uniQure N.V. (QURE)

uniQure (QURE) Stock Price & Analysis


QURE Stock Chart & Stats

Day’s Range$0 - $0
52-Week Range$12.52 - $28.26
Previous Close$19.3
Average Volume (3M)560.63K
Market Cap
Enterprise Value$696.81M
Total Cash (Recent Filing)$352.84M
Total Debt (Recent Filing)$142.89M
Price to Earnings (P/E)-7.1
May 01, 2023
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-2.72
Shares Outstanding46,815,109
10 Day Avg. Volume505,287
30 Day Avg. Volume560,634
Standard Deviation0.20
Financial Highlights & Ratios
Price to Book (P/B)2.82
Price to Sales (P/S)259.37
Price to Cash Flow (P/CF)2.90
P/FCF Ratio-9.20
Enterprise Value/Market CapN/A
Enterprise Value/Revenue6.54
Enterprise Value/Gross Profit6.76
Enterprise Value/Ebitda-6.45
Price Target Upside197.58% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8



Risk Analysis

Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products

Product Monthly Users

Sorry, No Data Available
There is no website visitor data available for this stock.



What was uniQure N.V.’s price range in the past 12 months?
uniQure N.V. lowest stock price was $12.52 and its highest was $28.25 in the past 12 months.
    What is uniQure N.V.’s market cap?
    Currently, no data Available
    When is uniQure N.V.’s upcoming earnings report date?
    uniQure N.V.’s upcoming earnings report date is May 01, 2023 which is in 40 days.
      How were uniQure N.V.’s earnings last quarter?
      uniQure N.V. released its earnings results on Feb 27, 2023. The company reported $0.15 earnings per share for the quarter, beating the consensus estimate of -$0.887 by $1.037.
        Is uniQure N.V. overvalued?
        According to Wall Street analysts uniQure N.V.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium
          Does uniQure N.V. pay dividends?
          uniQure N.V. does not currently pay dividends.
          What is uniQure N.V.’s EPS estimate?
          uniQure N.V.’s EPS estimate is -$0.89.
            How many shares outstanding does uniQure N.V. have?
            uniQure N.V. has 46,982,487 shares outstanding.
              What happened to uniQure N.V.’s price movement after its last earnings report?
              uniQure N.V. reported an EPS of $0.15 in its last earnings report, beating expectations of -$0.887. Following the earnings report the stock price went up 5.21%.
                Which hedge fund is a major shareholder of uniQure N.V.?
                Among the largest hedge funds holding uniQure N.V.’s share is Carlson Capital LP. It holds uniQure N.V.’s shares valued at 907K.


                  uniQure Stock Smart Score

                  The uniQure stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.
                  Learn more about TipRanks Smart Score

                  Company Description

                  uniQure N.V.

                  uniQure NV engages in the research, development, and commercialization of gene therapies. Its discoveries intend to treat hemophilia, Huntington's disease, glybera, and cardiovascular problems. The company was founded by Sander J. van Deventer in 1998 and is headquartered in Amsterdam, the Netherlands.


                  Forecast EPS vs Actual EPS

                  Similar Stocks
                  Price & Change
                  LAVA Therapeutics
                  Sangamo Biosciences

                  Popular Stocks

                  What's Included in PREMIUM?
                  Make informed decisions based on Top Analysts' activity
                  Know what industry insiders are buying
                  Get actionable alerts from top Wall Street Analysts
                  Find out before anyone else which stock is going to shoot up
                  Get powerful stock screeners & detailed portfolio analysis